Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITIZE HF: Sodium zirconium cyclosilicate to optimize RAAS inhibition in heart failure
2018-000175-33Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) and chronic heart failure (CHF) comparing Sodium zirconium cyclosilicate with Placebo (2 arms). Primary endpoint: Proportion of subjects in predefined categories at 3 months. Started Apr 2018; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
heart failure (HF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2018-000175-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000175-33.